Anastasios Dimou, M.D
Dr. Anastasios Dimou is a medical oncologist in the Department of Oncology and a member of the Lung Cancer Program at the Mayo Clinic in Rochester, Minnesota. He has a special focus on thoracic malignancies and melanoma, with a clinical focus that includes non-small cell lung cancer, small cell lung cancer, malignant pleural mesothelioma, thymic malignancies, and melanoma.[1]
Education and Career
Dr. Dimou earned his medical degree at the University of Athens Medical School in Athens, Greece. He completed a post-doctoral fellowship in Pathology Research at Yale University School of Medicine, then completed his internship and residency in Internal Medicine at the Albert Einstein Healthcare Network. He followed this training with a Fellowship in Hematology and Medical Oncology at the Medical University of South Carolina and a post-doctoral fellowship in Thoracic Oncology-Experimental Therapeutics at the University of Colorado School of Medicine, Anschutz Medical Campus.[1]
Dr. Dimou has been with the Mayo Clinic in Rochester, Minnesota since 2019. He is board-certified in Internal Medicine, Hematology, and Medical Oncology. He was granted a Career Development Award from the Department of Defense (DoD) Lung Cancer Research Program for his project titled, “HLA-Restricted Mechanisms of Progression in EGFR-Mutant Lung Cancer.”[3]
Professional Memberships
Dr. Dimou is an active member of several professional associations, including:[1]
- American Society of Clinical Oncology (ASCO)
- American Association for Cancer Research (AACR)
- International Association for the Study of Lung Cancer (IASLC)
Research
In addition to his clinical activities, Dr. Dimou is active in research, clinical trials, and education with a special interest in tumor microenvironment, tumor Immunology, and precision oncology. He has authored several scientific articles and presented his work in national and international meetings.
Dr. Dimou’s recent publications include:[footnote num=”2″}
- Proton Craniospinal Irradiation with Immunotherapy in Two Patients with Leptomeningeal Disease from Melanoma. Sener, U., Webb, M., Breen, W., Neth, B., Laack, N., Routman, D., Brown, P., Mahajan, A., Frechette, K., Dudek, A., Markovic, S., Block, M., McWilliams, R., Dimou, A.,…>; Journal of Immunotherapy and Precision Oncology. 2024 Feb 1
- Real-world Trends, Rural-urban Differences, and Socioeconomic Disparities in Utilization of Narrow versus Broad Next-generation Sequencing Panels. Zhao, Y., Fogarty, Z., Jiang, J., Liu, H., Wong, W., Wang, C., Dimou, A.>; Cancer Research Communications. 2024 Feb
- Toxicity From Sotorasib After Immune Checkpoint Inhibitors: A Note of Caution and Reflections of Future Advancements in the Field. Aakash Desai, Anastasios Dimou>; Journal of Thoracic Oncology. 2023 Oct 1
